Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

For more information on Age-Related Macular Degeneration go to the NHS website. If you've had a diagnosis, in addition to ...

Opthea Limited (NASDAQ:OPT), a biopharmaceutical company with a market capitalization of $894.5 million specializing in the ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

In response to the TGA's approval of a new drug to treat macular degeneration, UNSW researcher Dr Lisa Nivison-Smith provides context about the ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...